Reports Q3 revenue $110.399M, consensus $99.74M. “We are thrilled with the progress we have made these past few months, despite the challenges we have faced, and look forward to the many opportunities that we have in front of us. The SYFOVRE launch is back to a strong growth trajectory, underscoring the patient need and the strength of our product profile as we seek to make a difference in the lives of patients with GA,” said Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis. “We are also pleased with the progress of EMPAVELI, including the continued demand in PNH, the approval of the EMPAVELI Injector in the U.S., and the positive data from the Phase 2 NOBLE study in IC-MPGN and C3G. We believe all of this, combined with the corporate restructuring we undertook in August, puts our company in a stronger position to continue to create value for shareholders and deliver on our mission for patients now and in the future.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
- Apellis Pharmaceuticals call volume above normal and directionally bullish
- Biotech Alert: Searches spiking for these stocks today
- Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
- Apellis says journal published 24-month result from Phase 3 OAKS, DERBY studies